Flavone

Flavone

SCHEMBL1019491

O=c1cc(-c2ccccc2)oc2cc(OCc3ccccc3)c(OCc3ccccc3)c(O)c12.O=c1cc(-c2ccccc2)oc2ccccc12

nearest known ligand 0.73

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CREB1 P16220 6/20 0.73
BCHE P06276 2/20 0.61
ACHE P22303 2/20 0.61
ABCB1 P08183 5/20 0.60
MAPT P10636 3/20 0.60
L3MBTL1 Q9Y468 2/20 0.55
SMN1; SMN2 Q16637 3/20 0.53
TNKS O95271 3/20 0.53
GABRP O00591 2/20 0.53
GABRD O14764 2/20 0.53
TP53 P04637 2/20 0.53
CYP3A4 P08684 2/20 0.53
GABRA1 P14867 2/20 0.53
HPGD P15428 2/20 0.53
GABRB1 P18505 2/20 0.53
GABRG2 P18507 2/20 0.53
GABRB3 P28472 2/20 0.53
GABRA5 P31644 2/20 0.53
GABRA3 P34903 2/20 0.53
GABRA2 P47869 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL972006 0.94 CREB1 (0.83) CREB1BCHEACHEABCB1MAPT
SCHEMBL21335353 0.86 CREB1 (0.74) CREB1BCHEACHEABCB1MAPT
SCHEMBL30852784 0.86 CREB1 (0.77) CREB1BCHEACHEABCB1MAPT
SCHEMBL27797164 0.86 CREB1 (0.76) CREB1BCHEACHEABCB1MAPT
SCHEMBL971995 0.85 CREB1 (1.00) CREB1BCHEACHEABCB1MAPT
SCHEMBL971866 0.84 CREB1 (0.73) CREB1BCHEACHEABCB1MAPT
SCHEMBL2398442 0.81 HPGD (0.54) CREB1BCHEACHEABCB1MAPT
SCHEMBL969833 0.81 ABCB1 (0.71) CREB1BCHEACHEABCB1MAPT
SCHEMBL21515195 0.81 L3MBTL1 (0.69) CREB1BCHEACHEABCB1MAPT
SCHEMBL30852834 0.81 ABCB1 (0.65) CREB1BCHEACHEABCB1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7875650-B2 Baicalein analogs; enhances bioavailability of active compounds, especially orally administered compounds, by inhibition of P-glycoprotein 170 (P-gp 170) and/or CYP450 enzyme; 6-Acetoxy-5,7-dihydroxyflavone YALE UNIVERSITY (US) 2011-01-25 US disclosed